Europe comes to Canada as Lochmüller Lab hosts the annual meeting of the ProDGNE consortium

This August we welcomed our international colleagues of the ProDGNE consortium to Ottawa as we hosted the annual meeting of ProDGNE, the three-year transnational pre-clinical research project.  

Welcoming colleagues from around the world

From the from the 4th to the 5th of August we had the pleasure of hosting project investigators Drs. Fabrizio Pertusati (Lecturer, Cardiff University, UK), Paula Videira (Assistant Professor, Universidade NOVA de Lisboa, Portugal), Pierluigi Caboni (Professor, University of Cagliari, Italy) and Rüdiger Horstkorte (Professor, Martin-Luther University Halle-Wittenberg, Germany), patient representative Michela Onali (Gli Equilibristi HIBM, Italy), and several students and postdocs involved with ProDGNE. The group met over two days on the University of Ottawa campus to discuss the project deliverables, and share updates in the field of research and therapy development for GNE myopathy. 

Members of the ProdGNE consortium gathered around table.

Members of the ProdGNE consortium gathered in Ottawa for a working meeting.

Full agenda for both days of the meeting

Renowned researchers Drs Stella Mitrani-Rosenbaum (Hebrew University of Jerusalem) and David Wishart (University of Alberta, Edmonton) presented keynote talks to begin each day of the conference. Dr Mitrani-Rosenbaum presented past and current challenges of modeling GNE myopathy in zebrafish and mice, and Dr Wishart spoke on targeted metabolomics as a method to uncover biomarkers of rare diseases, covering his recent findings in GNE myopathy patient samples. After project updates from all work package leaders, collaborator Dr Andreas Roos delivered a presentation on biomarker research and proteins. Flash presentations were given by young investigators Mariana Barbosa (FCT NOVA), James Morewood (Cardiff University), Rebecca Rosenstengel, Elfrun Meyer and Linus Weilepp (MLU), and Alexa Derksen, Jarred Lau and Stephen Holland (Lochmüller Lab).

Exploring Ottawa

Following each day’s productive sessions, we had the chance to showcase Ottawa as Canada’s capital city. The group toured the parliament buildings and historic Byward Market and explored the Gatineau Park’s rolling hills and Pink Lake.

Michela Onali and Hanns Lochmüller on a path.

Michela Onali and Hanns Lochmüller explore the beautiful Gatineau park.

Looking ahead to the next project meeting

This meeting marks the end of ProDGNE’s second year. The consortium will reconvene for its final meeting in in April 2024 in Cagliari, Sardinia, Italy.  

Project funders

ProDGNE is funded under the European Joint Programme on Rare Diseases (EJP RD) Joint Transnational Call 2020 “Pre-Clinical Research to Develop Effective Therapies for Rare Diseases”. The project receives funding from the European Commission (EC) under the Horizon 2020 EJP-COFUND action and from national funding organisations. The Canadian contribution is funded by the Canadian Institutes of Health Research – Institute of Genetics. 

 

The ProdGNE consortium posing in front of building.

Read next...

Text reading: Solve-RD publication: Solve-RD flagship publication: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Photos of Dr Kiran Polavarapu, Dr Rachel Thompson, Dr Hanns Lochmüller.

Solve-RD flagship publication in Nature Medicine: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Patients and families with rare disorders often remain without a genetic diagnosis despite modern advances in diagnostic testing. Due to the rarity and global distribution...
New publication: Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis . Author's photos on the right, diagram from paper underneath title.

New Lab Publication Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis

Rhabdomyolysis is an acute failure of cellular homeostasis characterized by acute skeletal muscle damage triggered by trauma, infection, drugs, or strenuous exercise. Recurrent rhabdomyolysis is...
New lab publication on riboflavin transporter deficiency model

New Publication: Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish

Riboflavin transporter deficiency (RTD) is a rare genetic disorder in children, characterised by progressive sensorimotor and cranial neuronopathy caused by mutations in riboflavin transporter protein-encoding...
Congratulations CNMD Ottawa on 25 years of neuromuscular research. Photo of all former and current directors of the Centre.

uOttawa Eric Poulin Centre for Neuromuscular Disease Celebrates 25 Years of Neuromuscular Research

New co-directors Dr Mireille Khacho and Dr Hanns Lochmüller begin their tenure On November 25th the University of Ottawa Eric Poulin Centre for Neuromuscular Disease...
Clinical trial update - Canadian Patient First in the World to Receive Trial Drug in Argenx DOK7-CMS Study

Canadian Patient Dosed in Argenx DOK7-CMS Study

Our clinical research team at the NeuroMuscular centre of The Ottawa Hospital is excited to share that a Canadian patient affected by DOK-7 Congenital Myasthenic...
New lab publication - Brain malformations and seizures by impaired chaperonin function of TRiC

New Publication: Brain malformations and seizures by impaired chaperonin function of TRiC

We are excited to share a new publication from our research team! The study “Brain malformations and seizures by impaired chaperonin function of TRiC” uncovers...